Anthem Biosciences Limited has announced an earnings conference call to discuss its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The announcement was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call is being hosted in association with JM Financial Institutional Securities Limited.

Conference Call Schedule

The earnings call is set for Wednesday, May 20, 2026, with participation open to investors across multiple geographies. The schedule across time zones is as follows:

Participants are advised to dial in 10 minutes prior to the scheduled start time to ensure timely connectivity.

Company Participants

The following senior management representatives are scheduled to participate in the call:

• Mr. Ajay Bhardwaj — Managing Director and Chief Executive Officer
• Mr. Gawir Baig — Chief Financial Officer

Dial-In Details

Investors and analysts can join the call using the following dial-in numbers:

Investor Resources

Further details pertaining to the conference call will be made available on the company's official investor relations page at https://anthembio.com/investors/ . The intimation was filed with BSE Limited and the National Stock Exchange of India Limited on May 12, 2026, and was signed by Divya Prasad, Company Secretary & Compliance Officer (Membership No: A41438).

For further information regarding the conference call, investors may contact the following representatives at JM Financial Institutional Securities Limited:

Anthem Biosciences Limited has notified the stock exchanges of an upcoming Board of Directors meeting scheduled for Tuesday, May 19, 2026. The intimation has been filed pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The Board meeting has been convened to address key financial and corporate matters for the fiscal year. The following items are on the agenda:

The company's Bengaluru-based Board will deliberate on the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, alongside a possible recommendation of a final dividend for the same period.

Trading Window Closure

In line with regulatory requirements, Anthem Biosciences has enforced a trading window restriction for all insiders. As per the company's previous communication dated March 27, 2026, the trading window for dealing in the company's equity shares has been closed from April 01, 2026 and will remain shut until the close of trading hours on May 21, 2026—48 hours after the declaration of the financial results.

This measure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's own Code of Conduct governing the regulation, monitoring, and reporting of trading by employees and other connected persons.

Regulatory Compliance

The intimation has been duly signed by Divya Prasad, Company Secretary and Compliance Officer (Membership No: A41438), on May 12, 2026. The company has also made this disclosure available on its investor relations webpage at https://anthembio.com/investors/ . Anthem Biosciences, formerly known as Anthem Biosciences Private Limited, is headquartered at Bommasandra Industrial Area, Phase - I, Bengaluru - 560 099, Karnataka, India.